Back to search results

Observational Study for Cancer Research

This observational study aims to collect tumor tissue samples, and sometimes normal tissue, along with about 50 mL of blood from people with cancer. Researchers will use these samples to create preclinical models (like cell lines and models grown in mice) to better understand cancer biology. The goal is to identify new ways to treat cancer by testing new therapies and studying genes involved in tumor growth, specifically looking at RAF and targeted therapy mechanisms. This research could help design future clinical trials. You can join if you are 18 or older and are having a biopsy or surgery to remove tissue as part of your standard medical care or for research.

Study design
This is an observational study planning to enroll 50 participants. It is not a treatment study but focuses on collecting samples for future research.
What's involved
You would provide tissue samples during a planned biopsy or surgery, and about 50 mL of blood. A cheek swab might also be requested.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure the number of participants whose samples contribute to genomic, microbiome, and drug sensitivity studies for aggressive cancer, up to 6 years after tissue and blood collection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05324553

Patient Derived Preclinical Models

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~50 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Tissue CollectionBlood CollectionBuccal Swab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants accrued with genomic, microbiome, and drug sensitivity components of aggressive cancer.
Measured over Up to 6 years post tissue and blood collection

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Aaron S. Mansfield, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age and older
Patient is a good medical candidate for a standard of care or research biopsy or surgical procedure to obtain tissue

Exclusion

Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
Institutionalized or incarcerated patients
Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
Biopsy must not be considered more than minimal risk to the patient.
Have a contraindication to percutaneous biopsy including:

What this trial measures

  • Number of participants accrued with genomic, microbiome, and drug sensitivity components of aggressive cancer.Up to 6 years post tissue and blood collection

    Sequencing data from DNA and RNA will be integrated into a visualization platform to allow individualized study of patient tumor mutations, rearrangements, and RNA expression. Genomically informed analysis will be employed to select potential targets for drug screening in the patient-derived 3D models and determine how many specimens are able to grow as 3D models. In some cases, immunostain results may be analyzed for correlation to RNA expression levels.